Uptake and cytotoxicity of chitosan nanoparticles in human liver cells

Toxicology and Applied Pharmacology

Volumn 249, Issue 2, 2010, Pages 148-157

  Loh, Jing Wen ^a   Yeoh, George ^a,b   Saunders, Martin ^a   Lim, Lee Yong ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Chitosan nanoparticles; Hepatocytes; Necrosis; Toxicity

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALANINE AMINOTRANSFERASE; CHITOSAN; CYTOCHROME P450 3A4; NANOPARTICLE;

ARTICLE; AUTOPHAGY; BIOCOMPATIBILITY; CELL DEATH; CELL INTERACTION; CELL MEMBRANE; CELL NUCLEUS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; EXPOSURE; HUMAN; HUMAN CELL; LIVER CELL; LIVER TOXICITY; MEMBRANE DAMAGE;

ALANINE TRANSAMINASE; CELLS, CULTURED; CHITOSAN; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA, LIVER; NANOPARTICLES; TIME FACTORS;

EID: 77958182219     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.08.029     Document Type: Article

References (71)

1. Abraham P. Increased plasma biotinidase activity in rats with paracetamol-induced acute liver injury. Clin. Chim. Acta 2004, 349:61-65.
2. Ajun W., Yan S., Li G., Huili L. Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr. Polym. 2009, 75:566-574.
3. Amaravadi R.K., Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res. 2007, 13:7271-7279.
4. Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 2004, 11:1358-1361.
5. Awad M.E., Abdel-rahman M.S., Hassan S.A. Acrylamide toxicity in isolated rat hepatocytes. Toxicol. in Vitro 1998, 12:699-704.
6. Banerjee T., Singh A.K., Sharma R.K., Maitra A.N. Labeling efficiency and biodistribution of Technetium-99m labeled nanoparticles: interference by colloidal tin oxide particles. Pharm. Nanotechnol. 2005, 289:189-195.
7. Behrens I., Pena A.I.V., Alonso M.J., Kissel T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 2002, 19:1185-1193.
8. Chen F., Zhang Z.-R., Yuan F., Qin X., Wang M., Huang Y. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int. J. Pharm. 2008, 349:226-233.
9. Cheng X., Zhang F., Zhou G., Gao S., Dong L., Jiang W., Ding Z., Chen J., Zhang J. DNA/chitosan nanocomplex as a novel drug carrier for doxorubicin. Drug Deliv. 2009, 16:135-144.
10. Cosgrove B.D., King B.M., Hasan M.A., Alexopoulos L.G., Farazi P.A., Hendriks B.S., Griffith L.G., Sorger P.K., Tidor B., Xu J.J., Lauffenburger D.A. Synergistic drug-cytokine induction of hepatocellular death as an invitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol. Appl. Pharmacol. 2009, 237:317-330.
11. Dambach D.M., Andrews B.A., Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 2005, 33:17-26.
12. de Campos A.M., Diebold Y., Carvalho E.L.S., Sánchez A., Alonso M.J. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm. Res. 2004, 21:803-810.
13. de Salamanca A.E., Diebold Y., Calonge M., Garcia-Vazquez C., Callejo S., Vila A., Alonso M.J. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Investig. Ophthalmol. Vis. Sci. 2006, 47:1416-1425.
14. Dyer A.M., Hinchcliffe M., Watts P., Castile J., Jabbal-Gill I., Nankervis R., Smith A., Illum L. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm. Res. 2002, 19:998-1008.
15. Fernández-Urrusuno R., Calvo P., Remuñán-López C., Vila-Jato J.L., Alonso M.J. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. 2004, 16:1576-1581.
16. Fröhlich E., Kueznik T., Samberger C., Roblegg E., Wrighton C., Pieber T.R. Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol. Appl. Pharmacol. 2010, 242:326-332.
17. Gan Q., Wang T., Cochrane C., McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf., B 2005, 44:65-73.
18. Ge Y., Zhang Y., He S., Nie F., Teng G., Gu N. Fluorescence modified chitosan-coated magnetic nanoparticles for high-efficient cellular imaging. Nanoscale Res. Lett. 2009, 4:287-295.
19. Gibson G.G., Plant N.J., Swales K.E., Ayrton A., El Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002, 32:165-206.
20. Guengerich P.F. CYTOCHROME P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 1999, 39:1-17.
21. Guy J., Drabek D., Antoniou M. Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy. Mol. Biotechnol. 1995, 3:237-248.
22. Haas J., Kumar M.N.V.R., Borchard G., Bakowsky U., Lehr C.M. Preparation and characterization of chitosan and trimethyl-chitosan modified poly-(e-caprolactone) nanoparticles as DNA Carriers. AAPS PharmSciTech 2005, E22-E30.
23. Hewitt N.J., Lechon M.J., Houston J.B., Hallifax D., Brown H.S., Maurel P., Kenna J.G., Gustavsson L., Lohmann C., Skonberg C., Guillouzo A., Tuschl G., Li A.P., LeCluyse E., Groothuis G.M., Hengstler J.G. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 2007, 39:159-234.
24. Hood E. Fullerenes and fish brains: nanomaterials cause oxidative stress. Environ. Health Perspect. 2004, 112:568.
25. Huang M., Khor E., Lim L.Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm. Res. 2004, 21:344-353.
26. (R) CYP450 Screening Kits Protocol 2005.
27. Kim T.H., Park I.K., Nah J.W., Choi Y.J., Cho C.S. Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials 2004, 25:3783-3792.
28. Kompella U.B., Bandi N., Ayalasomayajula S.P. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting vegf expression. Investig. Ophthalmol. Vis. Sci. 2003, 44:1192-1201.
29. Krusekopf S., Rootsa I., Kleeberg U. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur. J. Pharmacol. 2003, 446:7-12.
30. Kulkarni J.S., Khanna A. Functional hepatocyte-like cells derived from mouse embryonic stem cells: a novel in vitro hepatotoxicity model for drug screening. Toxicol. in Vitro 2006, 20:1014-1022.
31. LeCluyse E.L., Alexandre E., Hamilton G.A., Viollon-Abadie C., Coon D.J., Jolley S., Richert L. Isolation and culture of primary human hepatocytes. Meth. Mol. Biol. 2005, 290:207-229.
32. Libbrecht L., Desmet V., Van Damme B., Roskams T. Deep intralobular extension of human hepatic Fprogenitor cells correlates with parenchymal inflammation in chronic viral hepatitis: can "progenitor cells" migrate?. J. Pathol. 2000, 192:373-378.
33. Lim S.T., Forbes B., Martin G.P., Brown M.B. In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate. AAPS PharmSciTech 2001, 2:1-14.
34. Loh, J. W., Schneider, J., Carter, M., Saunders, M., and Lim, L. Y., 2010. Spinning Disc Processing Technology: Potential for Large-scale Manufacture of Chitosan Nanoparticles. Journal of Pharmaceutical Sciences not available, ahead of print.
35. Loretz B., Bernkop-Schnurch A. In vitro evaluation of chitosan-EDTA conjugate polyplexes as a nanoparticulate gene delivery system. AAPS J. 2006, 80:E756-E764.
36. Lowes K.N., Brennan B.A., Yeoh G.Y., Olynyk J.K. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am. J. Pathol. 1999, 154:537-541.
37. Ma Z., Lim L.Y. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm. Res. 2003, 20:1812-1819.
38. Martien R., Loretz B., Sandbichler A.M., Schnürch A.B. Thiolated chitosan nanoparticles: transfection study in the Caco-2 differentiated cell culture. Nanotechnology 2008, 19:1-9.
39. McCloskey P., Edwards R.J., Tootle R., Selden C., Roberts E., Hodgson H.J.F. Resistance of three immortalized human hepatocyte cell lines to acetaminophen and N-acetyl-p-benzoquinoneimine toxicity. J. Hepatol. 1999, 31:841-851.
40. Mo Y., Lim L.-Y. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. J. Pharm. Sci. 2004, 93:20-28.
41. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
42. Morita M., Akai S., Hosomi H., Tsuneyama K., Nakajima M., Yokoi T. Drug-induced hepatotoxicity test using [gamma]-glutamylcysteine synthetase knockdown rat. Toxicol. Lett. 2009, 189:159-165.
43. Muzzarelli R.A.A. Biochemical significance of exogenous chitins and chitosans in animals and patients. Carbohydr. Polym. 1993, 20:7-16.
44. Nel A., Xia T., Mädler L., Li N. Toxic potential of materials at the nanolevel in science 2006, 622-627.
45. Nicolaas G.M., Susanne O., Janet A.H., Albertus G.D., Varum K.M., Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm. Res. 1997, 14:923.
46. O'Brien P., Haskins J.R. Invitro cytotoxicity assessment. Methods Mol. Biol. 2007, 356:415-425.
47. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with invitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
48. Oberdörster E. Manufactured nanomaterials (Fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health Perspect. 2004, 112:1058-1062.
49. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., VanDeun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
50. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
51. Qi L.F., Xu Z.R., Li Y., Jiang X., Han X.Y. In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells. World J. Gastroenterol. 2005, 11:5136-5141.
52. Qi L., Xu Z., Chen M. In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles. Eur. J. Cancer 2007, 43:184-193.
53. Ramaiah S.K. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem. Toxicol. 2007, 45:1551-1557.
54. Roskams T., De Vos R., Van Eyken P., Myazaki H., Van Damme B., Desmet V. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J. Hepatol. 1998, 29:455-463.
55. Sadeghi A.M.M., Dorkoosh F.A., Avadi M.R., Weinhold M., Bayat A., Delie F., Gurny R., Larijani B., Rafiee-Tehrani M., Junginger H.E. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm. 2008, 70:270-278.
56. Schipper N.G.M., Varum K.M., Artursson P. Chitosan as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation on drug transport across human epithelial (Caco-2) cells. Pharm. Res. 1996, 13:1686-1692.
57. Sereemaspun A. Inhibition of human cytochrome P450 enzymes by metallic nanoparticles: a preliminary to nanogenomics. Int. J. Pharmacol. 2008, 4:492-495.
58. Seymour L.W. Passive tumour-targeting of soluble macromolecules and drug conjugates CRC. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9:135-187.
59. Shi L.-E., Tang Z.-X. Adsorption of nuclease p1 on chitosan nano-particles. Braz. J. Chem. Eng. 2009, 26:435-443.
60. Sinha V.R., Singla A.K., Wadhawan S., Kaushik R., Kumria R., Bansal K., Dhawan S. Chitosan microspheres as a potential carrier for drugs. Int. J. Pharm. 2004, 274:1-33.
61. Sivaraman A., Leach J.K., Townsend S., Lida T., Hogan B.J., Stolz D.B., Fry R., Samson L.D., Tannenbaum S.R., Griffith L.G. A micro scale invitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr. Drug Metab. 2005, 6:569-591.
62. Smith J., Wood E., Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm. Res. 2004, 21:43-49.
63. Totino P.R.R., Riccio E.K.P., Corte-Real S., Daniel-Ribeiro C.T., Ferreira-da-Cruz M.F. Dexamethasone has pro-apoptotic effects on non-activated fresh peripheral blood mononuclear cells. Cell Biol. Int. 2006, 30:133-137.
64. Trapnell C.B., Jamis-Dow C., Klecker R.W., Collins J.M. Metabolism of Rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrob. Agents Chemother. 1997, 41:924-926.
65. van der Lubben I.M., Verhoef J.C., Borchard G., Junginger H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 2001, 14:201-207.
66. Wang T., Shankar K., Ronis M.J. Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes. Crit. Rev. Toxicol. 2007, 37:413-459.
67. Wang Y., Wang X., Luo G., Dai Y. Adsorption of bovin serum albumin (BSA) onto the magnetic chitosan nanoparticles prepared by a microemulsion system. Bioresour. Technol. 2008, 99:3881-3884.
68. Xu J.J., Diaz D., O'Brien P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem.-Biol. Interact. 2004, 150:115-128.
69. Zeng R., Tu M., Liu H., Zhao J., Zha Z., Zhou C. Preparation, structure, drug release and bioinspired mineralization of chitosan-based nanocomplexes for bone tissue engineering. Carbohydr. Polym. 2009, 78:107-111.
70. Zhang, A., London, R., Schulz, F. M., Giguère-Simmonds, P. W., Delriviere, L., Chandraratana, H., Hardy, K., Zheng, S., Olynyk, J. K., and Yeoh, G., 2009. Human Liver Progenitor Cell Lines are Readily Established from Non-tumorous Tissue Adjacent to Hepatocellular Carcinoma. Stem Cells and Development -not available-, ahead of print.
71. Zuhorn I.S., Kalicharan R., Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J. Biol. Chem. 2002, 277:18021-18028.